Press Releases - Pfizer
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Receives Authorization from Health Authority for Its 20 …
1 day ago · Pfizer announced today that the Hong Kong Department of Health (DoH) has approved the company's 20-valent Pneumococcal Conjugate Vaccine (PCV20) for active …
Pfizer Inc. (PFE) Latest Stock News & Headlines - Yahoo Finance
Get the latest Pfizer Inc. (PFE) stock news and headlines to help you in your trading and investing decisions.
Newsroom - Pfizer
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news. However, to ensure that customers, investors, and others receive the …
Pfizer Announces New Chief Scientific Officer and President, …
Nov 20, 2024 · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing …
CDC identifies possible safety issue with Pfizer’s updated ... - CNN
Jan 13, 2023 · Will approaching winter mean new Covid-19 surge? The US Centers for Disease Control and Prevention said Friday that there is a possible safety issue with the bivalent Covid …
Pfizer rolls out another cost-cutting program, sets $1.5 billion …
May 22, 2024 · U.S. drugmaker Pfizer on Wednesday launched a new multi-year program to reduce its expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost …
Pfizer lifts profit forecast as investors await turnaround
Jul 30, 2024 · Pfizer raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal for Seagen and strong sales of its heart disease drug as …
Pfizer lifts profit view on cost cuts, demand for COVID products
May 1, 2024 · Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected …
Pfizer cannot recoup $75 million from SEC insider trading …
Nov 19, 2024 · NEW YORK (Reuters) -A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission insider trading …